NDA Acceptance Removes Overhang on Puma Biotechnology (PBYI) - RBC

September 20, 2016 9:47 AM EDT
Get Alerts PBYI Hot Sheet
Price: $66.06 -1.78%

Rating Summary:
    7 Buy, 3 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 15 | Down: 23 | New: 57
Trade PBYI Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

RBC Capital analyst Simos Simeonidis weighed in on Puma Biotechnology (NYSE: PBYI) after Neratinib's NDA was accepted by FDA.

"Although this incremental positive was mostly expected, this does remove another overhang/bear argument from PBYI," Simeonidis. He continues to expect mid-2017 approval

The firm maintained a Sector Perform rating on PBYI.

For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.

Shares of Puma Biotechnology closed at $58.95 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

RBC Capital

Add Your Comment